News | April 15, 2025
Biocon Biologics secures market entry date for Yesafili in US
YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions
YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions
Sun Pharma has been involved in a patent infringement case with Incyte Corporation over LEQSELVI
The company has withdrawn all litigation against Vikas Lifecare Limited post withdrawal of the Alwar Case by VLL
Mylan and Novo Nordisk reach settlement of US patent litigation related to Ozempic
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced
EBITDA before special items falls 1.3 percent to € 4.41 billion
Philips also concluded an agreement with insurers to pay Philips EUR 540 million to cover Respironics recall-related product liability claims
Group sales came in at 47.637 billion euros, down 1.2% on a currency- and portfolio-adjusted basis
This agreement paves the way for the introduction of YESAFILI into the Canadian market
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
